Business Context and Reporting Period
Tvardi Therapeutics, Inc. (TVRD) filed a Form 8-K on March 31, 2026. The filing serves to announce financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in the filing text itself. The document solely references the issuance of a press release containing the results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. No specific guidance, outlook, or risk factors are enumerated in the text provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2026) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate based on the full-year 2025 results.
- Confirm any updates to clinical trial milestones or regulatory status mentioned in the press release.
- Check for any new debt covenants or liquidity events disclosed in the full press release.